Table 3.
Cases with anti-neuronal antibody testing
| Publication | Age | Sex | Sample | Antibodies tested | Results |
|---|---|---|---|---|---|
| Cases with myoclonus and ataxia | |||||
| Delorme et al. [11] | 72 | M | Serum and CSF | Unspecified | Negative |
| Dijkstra et al. [12] | 44 | M | Serum and CSF |
Intracellular: ANNA-1/Hu, ANNA-2/Ri, GAD65 Surface: AMPA-R, CASPR2, GABABR, LGI1, NMDA-R |
Negative |
| Grimaldi et al. [13] | 72 | M | Serum and CSF | Nerve tissue immunostaining; onconeural and membrane antigens, unspecified | Autoantibodies directed against Purkinje cells, striatal neurons, and hippocampal neurons. Onconeural and membrane antigens negative |
| Schellekens et al. [15] | 48 | M | Serum and CSF |
Serum: VGKC CSF: Paraneoplastic, unspecified |
Negative |
| Shah and Desai [16] | Middle-aged | M | Unspecified | Intracellular: Amphiphysin, ANNA-1/Hu, ANNA-2/Ri, GAD, Ma2 | Negative |
| Cases with myoclonus, without ataxia | |||||
| Khoo et al. [19] | 65 | F | Serum and CSF |
Intracellular: GAD Surface: CASPR2, DPPX, Gly-R, LGI1, NMDA-R |
Negative |
| Méndez-Guerro et al. [20] | 58 | M | Serum and CSF |
Intracellular: Amphiphysin, ANNA-1/Hu, ANNA-2/Ri, CV2, GAD65, Ma1, Ma2, PCA1/Yo, SOX1 Surface: AMPA-R1, AMPA-R1, CASPR-2, DPPX, GABABR, IgLON5, LGI1, NMDA-R |
Negative |
| Muccioli et al. [21] | 58 | M | Serum | Intracellular and surface, unspecified | Negative |
| Rábano-Suárez et al. [22] | 63 | M | Serum and CSF |
Intracellular: Amphiphysin, ANNA-1/Hu, ANNA-2/Ri, CV2, GAD65, Ma1, Ma2, PCA1/Yo, SOX1 Surface: AMPA-R1, AMPA-R2, CASPR2, DPPX, GABABR, LGI1, NMDA-R |
Negative |
| Rábano-Suárez et al. [22] | 76 | M | Serum |
Intracellular: Amphiphysin, ANNA-1/Hu, ANNA-2/Ri, CV2, GAD65, Ma1, Ma2, PCA1/Yo, SOX1 Surface: AMPA-R1, AMPA-R2, CASPR2, DPPX, GABABR, LGI1, NMDA-R |
Negative |
| Cases with ataxia, without myoclonus | |||||
| Delorme et al. [11] | 60 | F | Serum and CSF | Unspecified | Negative |
| Diezma-Martín et al. [26] | 70 | M | Serum | Onconeuronal, unspecified | Negative |
| Fadakar et al. [27] | 47 | M | Serum and CSF |
Intracellular: AGNA, ANNA-1/Hu, ANNA-2/Ri, CV2, GAD, Ma2, PCA1/Yo, PCA2, SOX1, Tr/DNER, Zic4 Surface: CASPR2, LGI1, mGluR1, NMDA-R |
Negative |
| Perrin et al. [37] | 64 | M | CSF | Unspecified | Negative |
| Perrin et al. [37] | 53 | F | CSF | Unspecified | Negative |
| Perrin et al. [37] | 51 | M | CSF | Unspecified | Negative |
| Perrin et al. [37] | 67 | M | CSF | Unspecified | Negative |
| Povlow and Auerbach [38] | 30 | M | Serum | Intracellular: GAD | Negative |
AGNA anti-glial nuclear antibody, AMPA-R alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, ANNA anti-neuronal nuclear antibody, CASPR2 contactin-associated protein 2, DNER delta/notch-like epidermal growth factor-related receptor, DPPX dipeptidyl-peptidase-like protein 6, GABABR gamma-aminobutyric acid type B receptor, GAD glutamic acid decarboxylase, GAD65 glutamic acid decarboxylase 65 kDa isoform, GlyR glycine receptor, LGI1 leucine-rich glioma inactivated 1, mGluR1 metabotropic glutamate receptor 1, NMDA-R N-methyl-d-aspartic acid receptor, PCA Purkinje cell cytoplasmic antibody, VGKC voltage-gated potassium channel, Zic4 zinc-finger protein 4